Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection

• Published in: Journal of translational medicine 2023-07, Vol.21 (1), p.450-450, Article 450
• Main Authors: Dal Bo, Michele, Polano, Maurizio, Ius, Tamara, Di Cintio, Federica, Mondello, Alessia, Manini, Ivana, Pegolo, Enrico, Cesselli, Daniela, Di Loreto, Carla, Skrap, Miran, Toffoli, Giuseppe
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Astrocytoma; Brain tumors; Care and treatment; Carmustine wafer; Central nervous system; Chemotherapy; Copy number; Datasets; Diagnosis; DNA methylation; Gene mutations; Genes; Genetic aspects; Genomics; Glioma; Gliomas; Health aspects; Information processing; Learning algorithms; Machine learning; Medical prognosis; Methods; Mutation; Nervous system; Next-generation sequencing; Oncology; Patients; Prognosis; Quality control; Signal transduction; Surgery; Survival; TOR protein; Tumor mutational burden; Tumors; Variables
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04308-y

Glioma grade 4 (GG4) tumors, including astrocytoma IDH-mutant grade 4 and the astrocytoma IDH wt are the most common and aggressive primary tumors of the central nervous system. Surgery followed by Stupp protocol still remains the first-line treatment in GG4 tumors. Although Stupp combination can prolong survival, prognosis of treated adult patients with GG4 still remains unfavorable. The introduction of innovative multi-parametric prognostic models may allow refinement of prognosis of these patients. Here, Machine Learning (ML) was applied to investigate the contribution in predicting overall survival (OS) of different available data (e.g. clinical data, radiological data, or panel-based sequencing data such as presence of somatic mutations and amplification) in a mono-institutional GG4 cohort. By next-generation sequencing, using a panel of 523 genes, we performed analysis of copy number variations and of types and distribution of nonsynonymous mutations in 102 cases including 39 carmustine wafer (CW) treated cases. We also calculated tumor mutational burden (TMB). ML was applied using eXtreme Gradient Boosting for survival (XGBoost-Surv) to integrate clinical and radiological information with genomic data. By ML modeling (concordance (c)- index = 0.682 for the best model), the role of predicting OS of radiological parameters including extent of resection, preoperative volume and residual volume was confirmed. An association between CW application and longer OS was also showed. Regarding gene mutations, a role in predicting OS was defined for mutations of BRAF and of other genes involved in the PI3K-AKT-mTOR signaling pathway. Moreover, an association between high TMB and shorter OS was suggested. Consistently, when a cutoff of 1.7 mutations/megabase was applied, cases with higher TMB showed significantly shorter OS than cases with lower TMB. The contribution of tumor volumetric data, somatic gene mutations and TBM in predicting OS of GG4 patients was defined by ML modeling.